SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Goronzy JJ, Weyand CM. Rheumatoid arthritis. In: Klippel JH, Weyand CM, Wortmann RL, editors. Primer on the rheumatic diseases. Atlanta: Arthritis Foundation; 1998. p. 15574.
  • 2
    Albers JM, Kuper HH, van Riel PL, Prevoo ML, van 't Hof MA, van Gestel AM, et al. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology (Oxford) 1999; 38: 42330.
  • 3
    Gremillion RB, van Vollenhoven RF. Rheumatoid arthhritis: designing and implementing a treatment plan. Postgrad Med 1998; 103: 1036.
  • 4
    Brooks P. Disease-modifying antirheumatic drugs, including methotrexate, gold, antimalarials, and D-penicillamine. Curr Opin Rheumatol 1995; 7: 16773.
  • 5
    American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 32846.
  • 6
    Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischman RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 47886.
  • 7
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 2539.
  • 8
    Ravinder M, William St Clair E, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concommitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 19329.
  • 9
    Laan RF, van Riel PL, van de Putte LB. Leflunomide and methotrexate. Curr Opin Rheumatol 2001; 13: 15963.
  • 10
    Smolen JF, Breedveld FC, Burmester GR, Combe B, Emery P, Kalden JR, et al. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Ann Rheum Dis 2000; 59: 5045.
  • 11
    Drummond MF, O'Brien BJ, Stoddart GL, Torrance G. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford Medical Publications; 1997.
  • 12
    Buxton MJ, Drummond MF, van Hout BA, Prince RL, Sheldon TA, Szucs T, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 21727.
  • 13
    Naimark D, Krahn M, Naglie G, Redelmeier DA, Detsky AS. Primer on medical decision analysis: part 5-working with Markov processes. Med Decis Making 1997; 17: 1529.
  • 14
    Welsing PM, Severens JL, Hartman M, van Gestel AM, van Riel PL, Laan RF. The development and validation of a Markov model for the economic evaluation of (new) treatments in rheumatoid arthritis. Int J Tech Asst Health Care. In press.
  • 15
    Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European league against rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 3440.
  • 16
    Hartman M, van Ede A, Severens JL, Laan RF, van de Putte LB, van der Wilt GJ. Economic evaluation of folate supplementation during methotrexate treatment in rheumatoid arthritis. J Rheumatol. In press.
  • 17
    Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001; 44: 198492.
  • 18
    Briggs A, Fenn P. Trying to do better than average: a commentary on statistical inference for cost-effectiveness ratio's. Health Econ 1997; 6: 4915.
  • 19
    Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985; 5: 15777.
  • 20
    Johannesson M. On the estimation of cost-effectiveness ratio's. Health Policy 1995; 31: 2259.
  • 21
    Van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight–week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44: 151524.
  • 22
    McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics 2000; 17: 50113.
  • 23
    Gabriel S, Drummond M, Maetzel A, Boers M, Coyle D, Welch V, et al. OMERACT 6 economics working group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 2003; 30: 88696.
  • 24
    Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000; 43: 231627.
  • 25
    Wong JB, Sing G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Arthritis Rheum 2000; 43: S144.
  • 26
    Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford) 2003; 42: 113.
  • 27
    Yazdani C, McLaughlin T, Cummins G, Doyle J. Comparison of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept. Am J Manag Care 2001; 7: S41926.
  • 28
    Ollendorf DA, Peterson AN, Doyle J, Huse DM. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population. Am J Manag Care 2002; 8: S20313.
  • 29
    Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum 2002; 47: 65561.